PTC Therapeutics (PTCT) Insider Trading & Ownership $65.80 -0.21 (-0.32%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PTC Therapeutics (NASDAQ:PTCT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)12Amount OfInsider Selling(Last 12 Months)$28.33M Get PTCT Insider Trade Alerts Want to know when executives and insiders are buying or selling PTC Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTCT Insider Buying and Selling by Quarter PTC Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/7/2025Mark Elliott BouldingVPSell3,375$63.43$214,076.25 10/6/2025Mark Elliott BouldingVPSell2,266$65.07$147,448.62 10/3/2025Allan Steven JacobsonDirectorSell12,000$65.00$780,000.00 10/3/2025Emma ReeveDirectorSell25,562$65.96$1,686,069.52 10/3/2025Mark Elliott BouldingVPSell22,655$65.82$1,491,152.10 10/3/2025Neil Gregory AlmsteadInsiderSell55,000$66.05$3,632,750.00 9/12/2025Mark Elliott BouldingVPSell24,585$61.34$1,508,043.90 9/11/2025Emma ReeveDirectorSell15,705$59.50$934,447.50 9/11/2025Mark Elliott BouldingVPSell22,664$61.00$1,382,504.00 9/9/2025David P SouthwellDirectorSell12,000$58.34$700,080.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/8/2025Eric PauwelsInsiderSell39,850$56.92$2,268,262.00 8/28/2025Allan Steven JacobsonDirectorSell1,667$50.15$83,600.05 8/28/2025Allan Steven JacobsonDirectorSell1,667$50.15$83,600.05 8/5/2025Matthew B KleinCEOSell10,739$51.74$555,635.86 7/15/2025Pierre GravierCFOSell2,516$49.46$124,441.36 5/16/2025Mark Elliott BouldingVPSell883$46.02$40,635.66 5/15/2025Mark Elliott BouldingVPSell1,929$46.18$89,081.22 4/22/2025Matthew B KleinCEOSell2,804$48.74$136,666.96 4/2/2025Lee Scott GoldenEVPSell897$46.95$42,114.15 3/13/2025Stephanie OkeyDirectorSell5,000$54.00$270,000.00 3/12/2025Mark Elliott BouldingVPSell15,521$53.30$827,269.30 3/4/2025Allan Steven JacobsonDirectorSell1,230$51.52$63,369.60 2/19/2025Christine Marie UtterCAOSell879$50.10$44,037.90 2/19/2025Eric PauwelsCEOSell1,378$50.10$69,037.80 2/19/2025Lee Scott GoldenEVPSell795$50.10$39,829.50 2/19/2025Mark Elliott BouldingVPSell1,333$50.10$66,783.30 2/19/2025Neil Gregory AlmsteadInsiderSell1,300$50.10$65,130.00 2/19/2025Pierre GravierCFOSell1,168$50.10$58,516.80 1/7/2025Christine Marie UtterCAOSell1,291$45.34$58,533.94 1/7/2025Eric PauwelsCEOSell1,599$45.34$72,498.66 1/7/2025Lee Scott GoldenEVPSell810$45.34$36,725.40 1/7/2025Mark Elliott BouldingVPSell1,543$45.34$69,959.62 1/7/2025Neil Gregory AlmsteadInsiderSell1,265$45.34$57,355.10 12/31/2024Matthew B KleinCEOSell8,279$45.16$373,879.64 12/2/2024Christine Marie UtterCAOSell17,800$51.77$921,506.00 12/2/2024Jerome B ZeldisDirectorSell24,000$51.50$1,236,000.00 12/2/2024Mark Elliott BouldingVPSell85,600$52.26$4,473,456.00 12/2/2024Neil Gregory AlmsteadInsiderSell69,550$52.06$3,620,773.00 (Data available from 1/1/2013 forward) PTCT Insider Trading Activity - Frequently Asked Questions Who is on PTC Therapeutics' Insider Roster? The list of insiders at PTC Therapeutics includes Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Jerome B Zeldis, Lee Scott Golden, Mark Elliott Boulding, Matthew B Klein, Michael Schmertzler, Neil Gregory Almstead, Pierre Gravier, Stephanie Okey, and Stuart Walter Peltz. Learn more on insiders at PTCT. What percentage of PTC Therapeutics stock is owned by insiders? 5.50% of PTC Therapeutics stock is owned by insiders. Learn more on PTCT's insider holdings. Which PTC Therapeutics insiders have been buying company stock? The following insider purchased PTCT shares in the last 24 months: Pierre Gravier ($198,737.00). How much insider buying is happening at PTC Therapeutics? Insiders have purchased a total of 7,700 PTCT shares in the last 24 months for a total of $198,737.00 bought. Which PTC Therapeutics insiders have been selling company stock? The following insiders have sold PTCT shares in the last 24 months: Allan Steven Jacobson ($1,284,369.70), Christine Marie Utter ($1,066,767.66), David P Southwell ($700,080.00), Emma Reeve ($2,620,517.02), Eric Pauwels ($2,474,519.80), Jerome B Zeldis ($2,000,800.00), Lee Scott Golden ($139,335.17), Mark Elliott Boulding ($10,373,774.95), Matthew B Klein ($1,488,310.48), Michael Schmertzler ($41,715.00), Neil Gregory Almstead ($7,392,848.60), Pierre Gravier ($260,149.54), and Stephanie Okey ($270,000.00). How much insider selling is happening at PTC Therapeutics? Insiders have sold a total of 556,011 PTC Therapeutics shares in the last 24 months for a total of $30,113,187.92 sold. PTC Therapeutics Key ExecutivesDr. Matthew B. Klein F.A.C.S. (Age 51)M.D., M.S., CEO & Director Compensation: $995.4kDr. Stuart W. Peltz Ph.D. (Age 64)Co-Founder, Senior Consultant & Member of Scientific Advisory Board Compensation: $1.54MDr. Allan Steven Jacobson Ph.D. (Age 78)Co-Founder, Chairman of Scientific Advisory Board & Independent Director Compensation: $145k3 recent tradesDr. Neil Almstead Ph.D. (Age 57)Chief Technical Operations Officer Compensation: $829.97kMr. Eric Pauwels (Age 63)Chief Business Officer Compensation: $847.67k1 recent tradesMr. Pierre Gravier M.S. (Age 38)Chief Financial Officer 1 recent tradesMs. Christine Utter (Age 46)Senior VP, Chief Accounting Officer & Head of People Services Compensation: $595.54kAlex KaneInvestor Relations OfficerMr. Mark Elliott Boulding (Age 63)Executive VP & Chief Legal Officer Compensation: $824.09k7 recent tradesMs. Jane BajVice President of Corporate Communications More Insider Trading Tools from MarketBeat Related Companies SMMT Insider Selling VTRS Insider Selling ROIV Insider Selling MRNA Insider Selling BBIO Insider Selling ELAN Insider Selling VRNA Insider Selling RVMD Insider Selling CYTK Insider Selling MRUS Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Marvell Insiders Buy Shares—Should Investors Follow Suit?This Insider Just Made a Massive Bet on Transocean's ComebackInsider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t WorryTop Insider Buys and Sells From September: Buy, Sell, or Hold? This page (NASDAQ:PTCT) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe best AI stock you aren’t watching (but Elon is)Elon Musk's AI empire is already being built... not in the spotlight, but in the background. One public cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
